Cerebrolysin
Also known as: FPE 1070, Porcine brain hydrolysate
Cerebrolysin (also called FPE 1070 or Porcine brain hydrolysate) is a peptide hydrolysate in the Neurotrophic peptide complex class. Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
For research use only.
Key Facts
- CAS
- 12656-49-6
- Molecular Weight (MW)
- Mixture of low-MW peptides
- Half-life
- Mixture; component PK not a single value
- FDA status
- Not Approved
- Administration Route
- Intramuscular
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Neuronal survival pathwaysNeurotrophic signaling
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 4
- Listed offers
- 6
- Median price per mg
- $1.79/mg
- Typical $1.21–$4.50/mg
Research summary
Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.
Peptide Library's Cerebrolysin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- 2–4 weeks typical in regional protocols
- Administration Route
- Intramuscular
- Reconstitution Guide
- —
- Injection Sites
- Abdomen
- Timing Notes
- Administer as a standalone; avoid mixing to preserve balance.
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Cerebrolysin is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular weight | Mixture of low-MW peptides |
|---|---|
| CAS number | 12656-49-6 |
| Half-life | Mixture; component PK not a single value |
| Appearance | Intramuscular injection (solution) |
| Formulation | Solution |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
Origin
Enzymatic hydrolysate of porcine brain proteins.
Targets
Studies
- Cerebrolysin for acute ischaemic stroke
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for vascular dementia
- The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Regulatory & research status
Cerebrolysin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Cerebrolysin side effects
Side Effects
- Injection reactions
- Agitation
- Headache
- Rare hypersensitivity
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Cerebrolysin: frequently asked questions
What is Cerebrolysin?
Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.
How does Cerebrolysin work?
Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
Is Cerebrolysin FDA approved?
No. Cerebrolysin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Cerebrolysin?
Reported half-life for Cerebrolysin is Mixture; component PK not a single value. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Cerebrolysin?
Compounds most often compared with Cerebrolysin include Semax, N-Acetyl Semax Amidate, Adamax and Selank. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2023External reference
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials — Neurol Sci, 2017External reference
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2015External reference
- Cerebrolysin for vascular dementia — Cochrane Database Syst Rev, 2013External reference
- The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts — Neuroscience, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Cerebrolysin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cerebrolysin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →